Seminar on GMP and Regulatory Expectations for Early IND Products

Overview:

This course will present, in one place, the regulations and guidelines that apply to early phase products. In some cases these will not be regulations, but needs that, if met, will increase the efficiency of activities as a product proceeds through the development process. The course will present these items in the order of product development from the point of R & D activities to the completion of Phase 2 clinical trials.

Any pharmaceutical worker who must deal with products both in early and later phases of development should attend this course in order to be aware of the regulatory requirements that will affect operations dealing with these products. The modifications to the GMPs for early phase products have modified the GMPs in such a way as to reduce requirements to allow more efficient work. At the same time some of the things that may appear to have changed, have not, and the pharmaceutical worker should be aware of this.

Who Will Benefit:

• Directors
• Managers
• Supervisors
• Regulatory Affairs
• Quality Assurance
• Quality Control

Agenda:

Day 1 Schedule:

Lecture 1: Very Early Stages

• The need for documentation of matters that will affect downstream work.
• The effects of ICH Q8
  • Impact on R & D activities
  • Risk analysis and design control at this stage.

Lecture 2: GLP requirements

• Animal studies
  • Toxicology and pharmacokinetics.
• Estimating the Maximum Safe Starting Dose
  • A review of the guidance document.

Lecture 3: Early Pre-IND Studies

• Understanding exploratory Studies
  • Definitions and the IND that will be withdrawn.
• Orphan Drugs
• Drugs studied under the Animal Rule
  • What they are and how to conduct the studies.

Lecture 4: Meetings and Preparing for the IND

• Information required for the Phase 1 IND
  • The CMC requirements that will be needed.
• Pre-IND Meetings with FDA

Day 2 Schedule:

Lecture 1: GMPs for Phase 1 IND products

• The scope of the guidance document
• The second guidance document covering the GMPs.

Lecture 2: GMPs for Phase 1 continued

• A presentation covering what GMPs are required at this stage.
• What has been omitted from the GMPs for Phase 1.

Lecture 3: Requirements for Phase 2 INDs

• The full GMPs resume, but do they?
• Phase 2 studies and the transition to full GMPs.
• CMC requirements.

Lecture 4: Preparing for IND Meetings

• Phase 1 meetings
• Pre-phase 2 meetings
• Phase 2 meetings

Speaker:

Founder & Principal, GXP Biotechnology, LLC 

Dr. Steven Kuwahara, Ph.D. is the founder and Principal of GXP Biotechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steve has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories . Steve has participated in the development of drugs and biologicals through all phases of clinical research and final product production.

Location: San Diego, CA Date: October 13th & 14th, 2016 Time: 9:00 AM to 6:00 PM

Venue: Four Points By Sheraton San Diego Downtown

Address: 1617 1st Avenue - San Diego, California, 92101 - United States

Register now and save $200.

Price: $1,295.00 (Seminar Fee for One Delegate - Without stay)

Until September 10, Early Bird Price: $1,295.00 from September 11 to October 11, Regular Price: $1,495.00

Price: $1,695.00 (Seminar Fee for One Delegate - With stay)

 Until September 10, Early Bird Price: $1,695.00 from September 11 to October 11, Regular Price: $1,895.00

Register for 5 attendees (With stay)   Includes   Price: $4,323.00 $8,475.00 You Save: $4,152.00 (49%)*

Quick Contact:

NetZealous DBA as GlobalCompliancePanel

Phone: 1-800-447-9407

Fax: 302-288-6884

Email: support@globalcompliancepanel.com      

Website: http://www.globalcompliancepanel.com

Registration Link - http://bit.ly/2bvZaoj-GMP-and-Regulatory

Follow on LinkedIn: https://www.linkedin.com/company/globalcompliancepanel